Novel Antibody Therapeutics Congress
October 7, 2019
Location: London Heathrow Marriott Hotel, Bath Road, Harlington, Hayes, United Kingdom
Dates: October 10-11, 2019
Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models
Benny Yang, Ph.D., Chief Scientific Officer & Director of Antibody Discovery, Biocytogen
Time: Thursday, October 10th, 10:20-10:50am
Biocytogen has recently developed RenMab™ Mouse, a fully human antibody mouse with its entire variable regions replaced by human Ig heavy chain and light chain. Combined with Biocytoegen’s existing inventory of single, double or triple humanized immune checkpoints mouse models and cytokine/cytokine receptors mouse models such as B-hCD40, B-h4-1BB, B-hOX40, B-hCD3e, B-hIL4/IL4Ra, B-hLI17A, B-hIL33, RenMab™ provides a streamlined therapeutic antibody discovery platform for human antibody generation, characterization, and rapid in vivo antibody efficacy screening. Hundreds of humanized models covering various therapeutic areas are under development. Together with dedicated preclinical teams with strong in vivo, ex vivo and in vitro capabilities, Biocytogen is poised to serve the biomedical community as an one-stop solution provider from target validation to IND application.
To learn more about the congress agenda, please go to http://www.global-engage.com/event/novel-antibody/.